A Multicenter, Open-Label, Phase I Study of MK0683 in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma.

Trial Profile

A Multicenter, Open-Label, Phase I Study of MK0683 in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Vorinostat (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 21 Aug 2012 Actual end date changed from Aug 2011 to Apr 2012 as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Actual patients number is 9 as reported by ClinicalTrials.gov.
    • 09 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top